|
1
|
Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand.
|
Cell
|
2012
|
2.45
|
|
2
|
X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.
|
Blood
|
2010
|
1.51
|
|
3
|
DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome.
|
Am J Hum Genet
|
2008
|
1.45
|
|
4
|
Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
|
Exp Neurol
|
2012
|
1.40
|
|
5
|
Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting.
|
J Gen Virol
|
2006
|
1.17
|
|
6
|
Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.
|
Proc Natl Acad Sci U S A
|
2012
|
1.06
|
|
7
|
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models.
|
Neoplasia
|
2009
|
1.06
|
|
8
|
Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling.
|
Cell Stem Cell
|
2010
|
0.97
|
|
9
|
Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats.
|
Diabetes
|
2004
|
0.94
|
|
10
|
Non-invasive bioluminescence imaging for monitoring herpes simplex virus type 1 hematogenous infection.
|
Microbes Infect
|
2006
|
0.90
|
|
11
|
Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction.
|
Neurobiol Dis
|
2006
|
0.90
|
|
12
|
Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts.
|
Oncotarget
|
2013
|
0.89
|
|
13
|
Behavioral characterization of a mouse model overexpressing DSCR1/ RCAN1.
|
PLoS One
|
2011
|
0.89
|
|
14
|
Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models.
|
Cancer Lett
|
2011
|
0.87
|
|
15
|
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
|
Neurobiol Dis
|
2012
|
0.87
|
|
16
|
Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing.
|
PLoS One
|
2011
|
0.86
|
|
17
|
Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors.
|
Oncology
|
2005
|
0.86
|
|
18
|
Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome.
|
Am J Hum Genet
|
2008
|
0.86
|
|
19
|
Connexin-26 is a key factor mediating gemcitabine bystander effect.
|
Mol Cancer Ther
|
2011
|
0.85
|
|
20
|
Adenovirus-mediated retinoblastoma 94 gene transfer induces human pancreatic tumor regression in a mouse xenograft model.
|
Clin Cancer Res
|
2004
|
0.85
|
|
21
|
Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells.
|
Biochim Biophys Acta
|
2010
|
0.84
|
|
22
|
Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo.
|
Hum Gene Ther
|
2005
|
0.81
|
|
23
|
Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy.
|
Mol Cancer Ther
|
2009
|
0.81
|
|
24
|
Targeting the CYP2B 1/cyclophosphamide suicide system to fibroblast growth factor receptors results in a potent antitumoral response in pancreatic cancer models.
|
Hum Gene Ther
|
2006
|
0.81
|
|
25
|
A novel Wiskott-Aldrich syndrome protein (WASP) complex mutation identified in a WAS patient results in an aberrant product at the C-terminus from two transcripts with unusual polyA signals.
|
J Hum Genet
|
2005
|
0.80
|
|
26
|
Wiskott-Aldrich syndrome in a female with skewed X-chromosome inactivation.
|
Blood Cells Mol Dis
|
2003
|
0.80
|
|
27
|
Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cells in vitro and in vivo.
|
FASEB J
|
2009
|
0.79
|
|
28
|
Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSVtk/GCV system.
|
J Gene Med
|
2002
|
0.78
|
|
29
|
Intramuscular SP1017-formulated DNA electrotransfer enhances transgene expression and distributes hHGF to different rat tissues.
|
J Gene Med
|
2004
|
0.78
|
|
30
|
Autoimmune thyroiditis after bone marrow transplantation in a boy with Wiskott-Aldrich syndrome.
|
J Pediatr Hematol Oncol
|
2002
|
0.77
|
|
31
|
Antitumor therapy based on cellular competition.
|
Hum Gene Ther
|
2009
|
0.77
|
|
32
|
Novel membrane cell projection defects in Wiskott-Aldrich syndrome B cells.
|
Int J Mol Med
|
2007
|
0.76
|
|
33
|
Combining oncolytic virotherapy and cytotoxic therapies to fight cancer.
|
Curr Pharm Des
|
2014
|
0.76
|
|
34
|
Identification and characterization of a novel splice-site mutation in a patient with Wiskott-Aldrich syndrome.
|
J Hum Genet
|
2003
|
0.76
|
|
35
|
Pitfalls and hopes in Down syndrome therapeutic approaches: in the search for evidence-based treatments.
|
Behav Genet
|
2006
|
0.75
|
|
36
|
Two novel mutations identified in the Wiskott-Aldrich syndrome protein gene cause Wiskott-Aldrich syndrome and thrombocytopenia.
|
Int J Mol Med
|
2007
|
0.75
|